1
|
Şen N, Mercan R, Geçmez G, Ediz B, Volkan O, Yilmaz-Oner S, Tezcan M. Psoriasis and family history of psoriasis may not affect disease severity of rheumatoid arthritis. Reumatismo 2022; 73. [DOI: 10.4081/reumatismo.2021.1453] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Accepted: 12/25/2021] [Indexed: 11/22/2022] Open
Abstract
The incidence of psoriasis in patients with rheumatoid arthritis (RA) is higher than in the general population. In addition, psoriasis may negatively affect the severity of rheumatological diseases in patients with autoinflammatory or autoimmune diseases. In this study, we evaluated the effect of psoriasis or a family history of psoriasis on the characteristics of RA. This is a cross-sectional study. We included 737 RA patients who met the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) RA Classification Criteria, but did not meet the CASPAR psoriatic arthritis criteria. Subsequently, we compared disease activity, the need for biologic therapy, the number of conventional synthetic disease-modifying anti-rheumatic drugs taken, the frequency of erosive disease and extra-articular involvement, glucocorticoid doses and the Stanford Health Assessment Questionnaire scores between patients with and without a history of psoriasis, and patients with and without a family history of psoriasis. Thirteen (1.8%) patients had psoriasis, while 58 (7.9%) had a family history of psoriasis in first- or seconddegree relatives. All outcome parameters were found to be similar between the groups. We show that concomitant psoriasis has no effect on the evaluated disease characteristics of RA.
Collapse
|
2
|
Malavia TA, Chaparala S, Wood J, Chowdari K, Prasad KM, McClain L, Jegga AG, Ganapathiraju MK, Nimgaonkar VL. Generating testable hypotheses for schizophrenia and rheumatoid arthritis pathogenesis by integrating epidemiological, genomic, and protein interaction data. NPJ SCHIZOPHRENIA 2017; 3:11. [PMID: 28560257 PMCID: PMC5441529 DOI: 10.1038/s41537-017-0010-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Revised: 01/13/2017] [Accepted: 01/13/2017] [Indexed: 02/04/2023]
Abstract
Patients with schizophrenia and their relatives have reduced prevalence of rheumatoid arthritis. Schizophrenia and rheumatoid arthritis genome-wide association studies also indicate negative genetic correlations, suggesting that there may be shared pathogenesis at the DNA level or downstream. A portion of the inverse prevalence could be attributed to pleiotropy, i.e., variants of a single nucleotide polymorphism that could confer differential risk for these disorders. To study the basis for such an interrelationship, we initially compared lists of single nucleotide polymorphisms with significant genetic associations (p < 1e-8) for schizophrenia or rheumatoid arthritis, evaluating patterns of linkage disequilibrium and apparent pleiotropic risk profiles. Single nucleotide polymorphisms that conferred risk for both schizophrenia and rheumatoid arthritis were localized solely to the extended HLA region. Among single nucleotide polymorphisms that conferred differential risk for schizophrenia and rheumatoid arthritis, the majority were localized to HLA-B, TNXB, NOTCH4, HLA-C, HCP5, MICB, PSORS1C1, and C6orf10; published functional data indicate that HLA-B and HLA-C have the most plausible pathogenic roles in both disorders. Interactomes of these eight genes were constructed from protein-protein interaction information using publicly available databases and novel computational predictions. The genes harboring apparently pleiotropic single nucleotide polymorphisms are closely connected to rheumatoid arthritis and schizophrenia associated genes through common interacting partners. A separate and independent analysis of the interactomes of rheumatoid arthritis and schizophrenia genes showed a significant overlap between the two interactomes and that they share several common pathways, motivating functional studies suggesting a relationship in the pathogenesis of schizophrenia/rheumatoid arthritis.
Collapse
Affiliation(s)
- Tulsi A. Malavia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA
| | - Srilakshmi Chaparala
- Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA USA
| | - Joel Wood
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA
| | | | | | - Lora McClain
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA
| | - Anil G. Jegga
- Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH USA
| | - Madhavi K. Ganapathiraju
- Department of Biomedical Informatics, School of Medicine, University of Pittsburgh, Pittsburgh, PA USA
| | - Vishwajit L. Nimgaonkar
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, USA
- Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, USA
| |
Collapse
|
3
|
Stelma F, Jansen L, Sinnige MJ, van Dort KA, Takkenberg RB, Janssen HLA, Reesink HW, Kootstra NA. HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy. J Viral Hepat 2016; 23:652-9. [PMID: 26945896 DOI: 10.1111/jvh.12525] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2015] [Accepted: 01/20/2016] [Indexed: 12/24/2022]
Abstract
Current treatment for chronic hepatitis B infection (CHB) consists of interferon-based therapy. However, for unknown reasons, a large proportion of patients with CHB do not respond to this treatment. Hence, there is a pressing need to establish response markers to select patients who will benefit from therapy and to spare potential nonresponders from unnecessary side effects of antiviral therapy. Here, we assessed whether HLA-C and KIR genotypes were associated with treatment outcome for CHB. Twelve SNPs in or near the HLA-C gene were genotyped in 86 CHB patients (41 HBeAg positive; 45 HBeAg negative) treated with peginterferon alfa-2a + adefovir. Genotyping of killer immunoglobin-like receptors (KIRs) was performed by SSP-PCR. One SNP in HLA-C (rs2308557) was significantly associated with combined response in HBeAg-positive CHB patients (P = 0.003). This SNP is linked to the HLA-C group C1 or C2 classification, which controls KIR binding. The combination of KIR2DL1 with its ligand HLA-C2 was observed significantly more often in HBeAg-positive patients with a combined response (13/14) than in nonresponders (11/27, P = 0.001). Patients with the KIR2DL1/C2 genotype had significantly higher baseline ALT levels (136 vs 50 U/L, P = 0.002) than patients without this combination. Furthermore, KIR2DL1-C2 predicted response independent of HBV genotype and ALT at baseline. HLA-C and KIR genotype is strongly associated with response in HBeAg-positive CHB patients treated with interferon-based therapy. In combination with other known response markers, HLA-C/KIR genotype could enable the selection of patients more likely to respond to interferon-based therapy.
Collapse
Affiliation(s)
- F Stelma
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.,Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands
| | - L Jansen
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.,Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands
| | - M J Sinnige
- Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands
| | - K A van Dort
- Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands
| | - R B Takkenberg
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands
| | - H L A Janssen
- Department of Gastroenterology and Hepatology, Erasmus Medical Center, Rotterdam, the Netherlands.,Toronto Centre for Liver Disease, Toronto Western & General Hospital, University Health Network, Toronto, Canada
| | - H W Reesink
- Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, the Netherlands.,Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands
| | - N A Kootstra
- Department of Experimental Immunology, Academic Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
4
|
ZHAO HUISHAN, YU HEFEN, MARTIN TRACEYA, TENG XU, JIANG WENG. The role of JAM-B in cancer and cancer metastasis (Review). Oncol Rep 2016; 36:3-9. [PMID: 27121546 PMCID: PMC4899009 DOI: 10.3892/or.2016.4773] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 12/08/2015] [Indexed: 12/31/2022] Open
Abstract
The junctional adhesion molecule B (JAM-B) is a multifunctional transmembrane protein, which belongs to the immunoglobulin superfamily (IgSF). JAM-B is localized to cell-cell contacts and enriched at cell junctions in epithelial and endothelial cells, as well as on the surface of erythrocytes, leukocytes, and platelets. Recent research in this field has shown that JAM-B plays an important role in numerous cellular processes, such as tight junction assembly, spermatogenesis, regulation of paracellular permeability, leukocytic transmigration, angiogenesis, tumor metastasis and cell proliferation. This study provides a new research direction for the diagnosis and treatment of relevant diseases. In this review, we briefly focus on what is currently known about the structure, function, and mechanism of JAM-B, with particular emphasis on cancer.
Collapse
Affiliation(s)
- HUISHAN ZHAO
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Capital Medical university, Beijing 100069, P.R. China
- Cancer Institute of Capital Medical university, Beijing 100069, P.R. China
- Beijing Key Laboratory for Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China
- Cardiff-China Medical Research Collaborative, Cardiff university School of Medicine, Heath Park, Cardiff CF14 4XN, UK
| | - HEFEN YU
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Capital Medical university, Beijing 100069, P.R. China
- Cancer Institute of Capital Medical university, Beijing 100069, P.R. China
- Beijing Key Laboratory for Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China
| | - TRACEY A. MARTIN
- Cardiff-China Medical Research Collaborative, Cardiff university School of Medicine, Heath Park, Cardiff CF14 4XN, UK
| | - XU TENG
- Department of Biochemistry and Molecular Biology, School of Basic Medicine, Capital Medical university, Beijing 100069, P.R. China
- Cancer Institute of Capital Medical university, Beijing 100069, P.R. China
- Beijing Key Laboratory for Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China
- Cardiff-China Medical Research Collaborative, Cardiff university School of Medicine, Heath Park, Cardiff CF14 4XN, UK
| | - WEN G. JIANG
- Cancer Institute of Capital Medical university, Beijing 100069, P.R. China
- Beijing Key Laboratory for Cancer Invasion and Metastasis Research, Beijing 100069, P.R. China
- Cardiff-China Medical Research Collaborative, Cardiff university School of Medicine, Heath Park, Cardiff CF14 4XN, UK
| |
Collapse
|
5
|
Prieto-Pérez R, Solano-López G, Cabaleiro T, Román M, Ochoa D, Talegón M, Baniandrés O, Estebaranz JLL, de la Cueva P, Daudén E, Abad-Santos F. New immune system genetic polymorphisms associated with moderate-to-severe plaque psoriasis: a case-control study. Br J Dermatol 2015; 172:1432-5. [PMID: 25639754 DOI: 10.1111/bjd.13585] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- R Prieto-Pérez
- Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - G Solano-López
- Dermatology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - T Cabaleiro
- Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| | - M Román
- Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - D Ochoa
- Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - M Talegón
- Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - O Baniandrés
- Dermatology Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - J L L Estebaranz
- Dermatology Service, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - P de la Cueva
- Dermatology Service, Hospital Universitario Infanta Leonor, Madrid, Spain
| | - E Daudén
- Dermatology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain
| | - F Abad-Santos
- Clinical Pharmacology Service, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria Princesa (IP), Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain
| |
Collapse
|